Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Biomarin Pharmaceuticals NASDAQ: BMRN-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

More stories below advertisement

Latest Press Releases

BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET
- PR Newswire - PRF - Tue Oct 12, 7:30AM CDT
PR Newswire - PRF - CMTX
Tue Oct 12, 7:30AM CDT
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on , at to discuss third quarter 2021 financial results and provide a general business update.
Phenylketonuria Drugs Market- Industry Demand, Share, Global Trend, Business Statistics, and Research Methodology by Forecast to 2029
- AmericaNewsHour - Thu Oct 7, 2:35AM CDT
AmericaNewsHour - CMTX
Thu Oct 7, 2:35AM CDT
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations
- PR Newswire - PRF - Mon Oct 4, 7:31AM CDT
PR Newswire - PRF - CMTX
Mon Oct 4, 7:31AM CDT
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the Company hired two industry veterans , M.D., Ph.D. as Senior Vice President, Chief Medical Officer and Head of Clinical Development and Ganesh Vedantham, as Senior Vice President, Technical Development filling two key strategic roles. 
Phenylketonuria Drugs Market- Key Findings, Company Profiles, Growth Strategy, Developing Technologies, Opportunities and Forecast by Regions till 2029
- AmericaNewsHour - Mon Oct 4, 1:07AM CDT
AmericaNewsHour - CMTX
Mon Oct 4, 1:07AM CDT
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN
- Newsfile Corp - Tue Sep 21, 3:55PM CDT
Newsfile Corp - CMTX
Tue Sep 21, 3:55PM CDT
New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc.("BioMarin" or the "Company") (NASDAQ: BMRN). Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN
- PR Newswire - PRF - Sun Sep 19, 11:48PM CDT
PR Newswire - PRF - CMTX
Sun Sep 19, 11:48PM CDT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN).  Such investors are advised to contact at  or 888-476-6529, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN
- PR Newswire - PRF - Thu Sep 9, 8:03PM CDT
PR Newswire - PRF - CMTX
Thu Sep 9, 8:03PM CDT
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN). Such investors are advised to contact at or 888-476-6529, ext. 7980.
Phenylketonuria Drugs Market- Demand, Trends, Share,Global Demand Analysis and Opportunity Outlook 2029
- AmericaNewsHour - Wed Sep 8, 1:26AM CDT
AmericaNewsHour - CMTX
Wed Sep 8, 1:26AM CDT
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
- PR Newswire - PRF - Mon Sep 6, 1:00AM CDT
PR Newswire - PRF - CMTX
Mon Sep 6, 1:00AM CDT
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study.  The Phearless study is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy, in adults with phenylketonuria (PKU).  The FDA's clinical hold was based on interim safety findings from a pre-clinical, non-GLP pharmacology study.  
Global Phenylketonuria Drugs Market- Analysis By Recent Trends, Development And Growth Forecast To 2027
- AmericaNewsHour - Fri Sep 3, 8:51AM CDT
AmericaNewsHour - CMTX
Fri Sep 3, 8:51AM CDT
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies